Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04409236 · ClinicalTrials.gov registry record · Phase 3

Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking

A Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid System Neoplasm, sponsored by Fred Hutchinson Cancer Center.

Active
Registry status
Phase 3
Development phase
427
Enrollment target
1
Study location

NCT04409236 is a Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid System Neoplasm that is active but no longer recruiting, run by Fred Hutchinson Cancer Center. The registered enrollment target is 427 participants, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04409236, a Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid System Neoplasm, is active but no longer recruiting, sponsored by Fred Hutchinson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
427 participants
Enrollment target
1
Study location

Study Summary

This phase III trial compares the Quit2Heal smoking cessation smartphone application (app) to the QuitGuide app in helping cancer patients quit smoking. Both apps provide tools to cope with urges to smoke, step-by-step guides for quitting smoking, help in planning for quitting and staying tobacco-free, and scientifically-based recommendations for how to select medications that aid in smoking cessation.

Interventions

  • OTHER Survey Administration
  • BEHAVIORAL QuitGuide
  • BEHAVIORAL Quit2Heal

Study Locations (1)

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 427 participants
Start Date 2021-07-19
Est. Completion 2026-09-11
Phase Phase 3

Sponsor

Fred Hutchinson Cancer Center

483 total trials

What the Registry Record Tells You About NCT04409236

The ClinicalTrials.gov registry entry for NCT04409236 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 427 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (62% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Survey Administration is the first listed.

NCT04409236 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT04409236 about?

NCT04409236 is a clinical study titled "Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking". This phase III trial compares the Quit2Heal smoking cessation smartphone application (app) to the QuitGuide app in helping cancer patients quit smoking. Both apps provide tools to cope with urges to smoke, step-by-step guides for quitting smoking, help in planning for quitting and staying tobacco-fr...

What is the current status of trial NCT04409236?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 427 participants. The study started on 2021-07-19. Estimated completion is 2026-09-11.

What conditions does trial NCT04409236 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm.

What interventions are being tested in trial NCT04409236?

The interventions under investigation include: Survey Administration (OTHER), QuitGuide (BEHAVIORAL), Quit2Heal (BEHAVIORAL).

Who is sponsoring clinical trial NCT04409236?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04409236 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.